SynthesisBMC public health2025
Gas station heroin- tianeptine and its impact: a systematic review and exploratory analysis.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brief report: Meth, tranq, gas station heroin & other drugs complicating addiction treatment.The American journal on addictions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTianeptine, a drug approved in some countries for the treatment of major depressive disorder, has raised significant public health concerns due to its potential for misuse and addiction. Its activity at the mu-opioid receptor along with its availability as a dietary supplement in certain regions, raises concerns about overdose, toxicity, and its contribution to the opioid crisis. Despite recognition of its addictive potential for over two decades, systematic data on misuse patterns, associated risk factors, and effective treatment strategies remain limited. This study investigates demographic/regional trends in tianeptine misuse, examines the influence of dosage, administration routes, and co-administration with other substances on overdose risk, and evaluates the efficacy of naloxone and other treatments in managing tianeptine toxicity and withdrawal symptoms.
methodsFollowing PRISMA 2020 guidelines, our systematic review (PROSPERO ID: CRD42024521671) searched PubMed, Embase, PsycINFO, Web of Science, Cochrane Library, Google Scholar, and ClinicalTrials.gov. The quality of included studies was assessed using the JBI checklist, and exploratory analysis was conducted in R (v.4.3.3). From 1,562 identified records, 25 studies met inclusion criteria.
resultsTianeptine misuse demonstrated notable regional variations, with North America accounting for 40/52 (76.92%) of cases, followed by Asia 8/52 (15.38%) and Europe 4/52 (7.69%) (X²=44.9231, p < 0.0001). The majority of users were male 29/52 (55.77%) (X²=0.6923, p = 0.4054), and oral ingestion was the predominant route 37/52 (71.15%), while intravenous use accounted for 5/52 (9.62%) (X²=88.3846, p < 0.0001). Habitual misuse was documented in 30/52 (57.69%) of cases (X²=1.2308, p = 0.2673). Overdose occurred in 18/52 (34.62%) of cases (X²=4.9231, p = 0.0265), frequently associated with high doses up to 20 g daily and co-administration with alcohol 6/52 (11.54%) or benzodiazepines 5/52 (9.62%) (X²=68.5932, p < 0.0001). Naloxone reversed symptoms in 9/52 (17.31%) of treated cases (X²=22.2308, p < 0.0001). Withdrawal symptoms were observed in 22/52 (42.31%) of cases (X²=21.3846, p < 0.0001), with management strategies including buprenorphine 4/52 (7.69%) and supportive care 4/52 (7.69%) (X²=44.0000, p < 0.0001).
conclusionTianeptine misuse, characterized by escalating doses, habitual use, and co-administration with other substances, poses significant risks. Its easy availability and lack of regulation further exacerbate its public health impact. Targeted prevention, regulation, and treatment interventions are urgently needed to address these challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.